TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07610525: Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial

Sponsor: M.D. Anderson Cancer Center · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 200 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT07610525 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07610525 Rescue Dossier →